Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single Ascending Dose Study of Intraperitoneal Triferic (Ferric Pyrophosphate Citrate) in Patients on Chronic Peritoneal Dialysis

Next Previous
X
Search
Trial Profile

Single Ascending Dose Study of Intraperitoneal Triferic (Ferric Pyrophosphate Citrate) in Patients on Chronic Peritoneal Dialysis

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jan 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ferric pyrophosphate (Primary) ; Ferric pyrophosphate
  • Indications Iron deficiency anaemia
  • Focus Pharmacokinetics
  • Sponsors Rockwell Medical Technologies

    • Most Recent Events

    • 09 May 2019 According to a Rockwell Medical Technologies media release, data from this trial was presented at the 39th Annual Dialysis Conference in March 2019.
    • 18 Mar 2019 According to a Rockwell Medical Technologies media release, the data from two studies including this study will be presented at the Annual Dialysis Conference, the largest multi-disciplinary conference on dialysis Mar 16-19 2019.
    • 02 May 2018 According to a Rockwell Medical Technologies media release, data from this trial will be presented at the 17th Congress of the International Society for Peritoneal Dialysis (ISPD) 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top